AB SCIEX announced last year, for example, that through its distribution romantic relationship with Labindia, it provided a meals safety testing alternative to six major laboratories under the pesticides monitoring network task by India’s federal government. This was part of a task with the Ministry of Agriculture to greatly help reinforce new food safety standards through better monitoring for contamination. ‘Expansion of Stomach SCIEX’s commercial procedures in India will reinforce our placement and help us build on the success of Labindia’s mass spectrometry business as well as execute on our development technique,’ said Umesh Pawa, Controlling Director, Stomach SCIEX India.The principal driver for the boost was revenue recognized in conjunction with AVEO’s collaboration contract with Astellas. Research and development expenditure for the first one fourth of 2011 was $38.0 million compared with $22.6 million for the first quarter of 2010. The upsurge in R&D spending was mainly because of the expense of amounts because of Kyowa Hakka Kirin from the up-front license payment received from Astellas along with an increase in clinical costs associated with ficlatuzumab, partially offset by reimbursable quantities under the price posting provisions of AVEO’s collaboration contract with Astellas.